Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (48)

« Back to Publications

Myelin oligodendrocyte glycoprotein antibody-associated disease and relapse risk: Effects of smoking and vascular risk factors.

Yeh WZ. et al, (2026), Mult Scler

Prediction of relapse in myelin oligodendrocyte glycoprotein antibody-associated disease: external validation of the MOG-AR score

Yeh WZ. et al, (2026), Journal of Neurology, 273

Optimal strategies for treatment discontinuation in MOG antibody-associated disease

Yeh WZ. et al, (2026), Brain

Pregnancy-Related Clinical Outcomes in Women with Moderate-Severe Multiple Sclerosis Disability

Shipley J. et al, (2026), MULTIPLE SCLEROSIS JOURNAL, 32

Epstein-Barr Virus Induced Epigenetic Changes in MS

Lea R. et al, (2026), MULTIPLE SCLEROSIS JOURNAL, 32

The impact of CGRP monoclonal antibodies on cytokine expression in chronic migraine: a cohort study

Ray JC. et al, (2025), Journal of Neurology, 272

Pregnancy-Related Disease Outcomes in Women With Moderate to Severe Multiple Sclerosis Disability

Shipley J. et al, (2025), JAMA Network Open, 8, e2531581 - e2531581

C4 genetic structural variations affect multiple sclerosis risk and progression

Lin X. et al, (2025)

Progression independent of relapse activity and relapse-associated worsening in seronegative NMOSD: an international cohort study

Siriratnam P. et al, (2025), Journal of Neurology, 272

Consensus recommendations on multiple sclerosis management in Australia and New Zealand: part 2

Shipley J. et al, (2025), Medical Journal of Australia, 222, 365 - 371

Consensus recommendations on multiple sclerosis management in Australia and New Zealand: part 1

Shipley J. et al, (2025), Medical Journal of Australia, 222, 356 - 364

Predictors of relapse risk and treatment response in AQP4-IgG positive and seronegative NMOSD: A multicentre study

Siriratnam P. et al, (2025), Journal of Neurology, Neurosurgery & Psychiatry, 96, 361 - 369

Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease & Relapse Risk: Effects of Smoking and Vascular Risk Factors

Yeh W. et al, (2025), MULTIPLE SCLEROSIS JOURNAL, 31, 127 - 127

Predictors of Relapse and Disability Progression After Pregnancy in Women with Moderately Severe Multiple Sclerosis Disability

Shipley J. et al, (2025), MULTIPLE SCLEROSIS JOURNAL, 31, 514 - 517

Optimal strategy for treatment discontinuation in monophasic and relapsing MOGAD

Yeh W. et al, (2025), MULTIPLE SCLEROSIS JOURNAL, 31, 1379 - 1380

Load More